Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Equillium (Nasdaq: EQ) announced management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.
Members of management will also be available for investor meetings with registered conference attendees.
Positive
- None.
Negative
- None.
News Market Reaction – EQ
In the Feb 25 session, EQ declined 4.69%, reflecting a moderate negative market reaction. Argus tracked a trough of -15.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Inducement grants | Neutral | +0.0% | Inducement stock options for two new employees under 2024 Inducement Plan. |
| Nov 20 | Investor conferences | Neutral | +0.0% | Planned participation in two early December 2025 healthcare investor conferences. |
| Nov 13 | Earnings and financing | Negative | -9.1% | Q3 2025 loss, revenue at $0, and private placement funding operations through 2027. |
| Nov 04 | Investor conferences | Neutral | -7.1% | Announcements of Stifel presentation and Jefferies meetings with webcast access. |
| Nov 03 | Inducement grant | Neutral | +9.9% | Stock option inducement grant to a new employee under 2024 Inducement Plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: neutral items like inducement grants and some conference appearances saw flat or diverging moves, while a negative earnings update aligned with a notable selloff.
Over the past months, Equillium news has centered on financing, governance, and investor outreach. A Q3 2025 update on Nov 13, 2025 detailed a private placement of up to $50.0M and a net loss of $4.2M, with a -9.09% price reaction. Multiple conference participation announcements in November 2025 and inducement grants in October 2025 and February 2026 had modest or mixed price impacts. Today’s Leerink conference participation fits this pattern of ongoing investor engagement activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.
Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.
About Equillium
Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
For more information, visit www.equilliumbio.com.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
